Compare
Idexx Laboratories Inc vs Lantheus Holdings, Inc. vs Neogen Corp vs Myriad Genetics Inc
| Latest fiscal year | Idexx Laboratories Inc IDXX | Lantheus Holdings, Inc. LNTH | Neogen Corp NEOG | Myriad Genetics Inc MYGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-05-31 | 2025-12-31 |
| Revenue | $4.30B | $1.54B | $870.40M | $824.50M |
| Revenue growth (YoY) | +10.4% | +0.5% | -2.7% | -1.6% |
| Gross margin | 61.8% | 61.1% | 46.9% | 69.9% |
| Operating margin | 31.6% | 20.2% | -2.5% | -47.0% |
| Net margin | 24.6% | 15.2% | -0.9% | -44.4% |
| Net income | $1.06B | $233.56M | -$7.90M | -$365.90M |
| EPS (Diluted) | $13.08 | $3.41 | -$0.04 | -$3.95 |
| Operating cash flow | $1.18B | $390.14M | $83.20M | $1.80M |
| Free cash flow | $1.06B | n/a | $31.90M | n/a |
| Cash & equivalents | $180.07M | $359.12M | $185.50M | $149.60M |
| Total assets | $3.35B | $2.23B | $3.35B | $706.60M |
| Total liabilities | $1.75B | $1.14B | $1.25B | $338.60M |
| Shareholders' equity | $1.61B | $1.09B | $2.09B | $368.00M |
| Return on year-end equity | 66.0% | 21.4% | -0.4% | -99.4% |
| Shares outstanding | 79.71M | 64.59M | 217.70M | 93.50M |
Revenue, most recent five fiscal years
| Fiscal year | Idexx Laboratories Inc | Lantheus Holdings, Inc. | Neogen Corp | Myriad Genetics Inc |
|---|---|---|---|---|
| Latest | $4.30B Ended 2025-12-31 | $1.54B Ended 2025-12-31 | $870.40M Ended 2026-05-31 | $824.50M Ended 2025-12-31 |
| 1 year earlier | $3.90B Ended 2024-12-31 | $1.53B Ended 2024-12-31 | $894.70M Ended 2025-05-31 | $837.60M Ended 2024-12-31 |
| 2 years earlier | $3.66B Ended 2023-12-31 | $1.30B Ended 2023-12-31 | $924.20M Ended 2024-05-31 | $753.20M Ended 2023-12-31 |
| 3 years earlier | $3.37B Ended 2022-12-31 | $935.06M Ended 2022-12-31 | $822.45M Ended 2023-05-31 | $678.40M Ended 2022-12-31 |
| 4 years earlier | $3.22B Ended 2021-12-31 | $425.21M Ended 2021-12-31 | $527.16M Ended 2022-05-31 | $690.60M Ended 2021-12-31 |